As of 6 Nov 2026, CORONA Remedies trades at 72.1× trailing earnings, above the industry P/E of 37.3×. It earns ROCE of 29% and ROE of 28%, and sales and net profit grew 17% and 30% a year over 3 years. Its dividend yield is 0.4%, and debt is 0.14× equity. It is a small-cap company with a market cap of ₹14,929 Cr, ranked 4th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 70% over the past year.
- ₹2,372.60
- ₹2,584.00
- ₹2,358.10
- ₹2,379.80
- 1.5 L
Health check
- ReturnsAhead
+69.7% over a year, better than 6 of 7 peers.
- Price tagPricier
P/E 72.1 vs industry 37.3.
- GrowthSteady
Sales +16.6%, profit +29.7% a year over 3 years.
- ProfitabilityStrong
ROCE 29.0% vs peer median 22.9%.
- Balance sheetFair
Debt 0.14× equity, interest covered 53.6×, Piotroski 5 of 9.
- Red flags1 to check
P/E of 72.1 against an industry P/E of 37.3.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹14,929 Cr
- Small cap
- P/E
- 72.1
- Industry 37.3
- Price to book
- 18.55
- Peers 9.15
- Dividend yield
- 0.41%
- ROE
- 28.3%
- Peers 20.9%
- ROCE
- 29.0%
- Peers 22.9%
- Debt to equity
- 0.14
- Debt ₹115 Cr
- EPS (TTM)
- ₹33.85
- Face value ₹10
- OPM (TTM)
- 20.2%
- Net margin 13.3%
- Sales growth
- +22.2%
- Latest quarter vs a year ago
- Profit growth
- +15.3%
- Latest quarter vs a year ago
- Price to sales
- 9.58
- EV/EBITDA 45.1
Strengths and risks
Strengths
- Return on equity of 28.3%.
- Return on capital employed of 29.0%.
- Quarterly sales up 22.2% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- P/E of 72.1 against an industry P/E of 37.3.
About CORONA Remedies
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
- Headquarters
- Ahmedabad
- Employees
- 5,153
- Sector
- Healthcare
- ISIN
- INE02ZQ01018
- Website
- coronaremedies.com
Price range
- Avg volume (3M)
- 42.2K
- 1-year return
- plus 69.7%
- From 52-week high
- minus 5.5%
Peers · Drug Manufacturers - General
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLAXOGlaxosmithkline Pharmaceuticals | 2,524.80 | plus 0.98% | 42,772 | 37.3 | 22.73 | 55.4% | 63.9% | 34.1% | 5.7% | 19.3% | 2.26% | minus 6.0% |
| RUBICONRubicon Research | 1,659.30 | minus 4.67% | 27,468 | 95.6 | 19.38 | 23.6% | 19.1% | 23.3% | – | – | 0.09% | plus 166.7% |
| PFIZERPfizer | 3,856.00 | minus 0.02% | 17,640 | 23.2 | 4.02 | 22.9% | 20.9% | 36.7% | 1.3% | 5.0% | 1.94% | minus 24.6% |
| CORONACORONA Remedies | 2,441.10 | plus 2.58% | 14,930 | 72.1 | 18.55 | 29.0% | 28.3% | 21.3% | 16.6% | 29.7% | 0.41% | plus 69.7% |
| MARKSANSMarksans Pharma | 303.70 | minus 3.20% | 13,764 | 24.6 | 4.13 | 17.5% | 15.2% | 22.5% | 16.7% | 16.2% | 0.30% | plus 68.0% |
| SYMBIOTECSymbiotec Pharmalab | 1,513.60 | plus 19.04% | 9,726 | 103.5 | 8.26 | 14.3% | 11.2% | 10.7% | 16.8% | 67.3% | 0.00% | plus 37.9% |
| SANOFICONRSanofi Consumer Healthcare India | 3,420.20 | minus 0.69% | 7,888 | 28.2 | 22.64 | – | 80.4% | 37.8% | – | – | 2.19% | minus 29.5% |
| SANOFISanofi India | 3,283.10 | minus 2.75% | 7,561 | 20.7 | 9.15 | – | 44.1% | 28.0% | – | – | 3.75% | minus 28.9% |
| Median of 7 peers | – | −0.69% | 13,764 | 28.2 | 9.15 | 22.9% | 20.9% | 28.0% | 11.2% | 17.7% | 1.94% | −6.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| 347 | 361 | 342 | 353 | 441 | |
| 277 | 283 | 276 | 291 | 345 | |
| 69.8 | 78.5 | 66.3 | 62 | 96 | |
| 20.1% | 21.7% | 19.4% | 17.6% | 21.7% | |
| 1.8 | 2.4 | 19.1 | 4.4 | 2.6 | |
| 2 | 1.9 | 1.7 | 1.4 | 2.8 | |
| 8.9 | 9.2 | 9.5 | 10.3 | 15.1 | |
| – | – | −19.1 | – | – | |
| 60.7 | 69.8 | 55.2 | 54.7 | 80.8 | |
| 23.9% | 25.0% | 25.2% | 17.2% | 25.3% | |
| 46.2 | 52.3 | 41.3 | 45.3 | 60.3 | |
| 7.55 | 8.55 | 6.75 | 7.41 | 9.86 |
Profit & loss
- Sales CAGR 3Y
- +16.6%
- Profit CAGR 3Y
- +29.7%
- EPS CAGR 3Y
- +29.7%
- ROE
- 28.3%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 884 | 1,014 | 1,196 | 1,401 | |
| – | +14.7% | +17.9% | +17.2% | |
| 755 | 858 | 955 | 1,107 | |
| 128 | 156 | 241 | 294 | |
| 14.5% | 15.4% | 20.1% | 21.0% | |
| 5.2 | 3.1 | 3.7 | 8.5 | |
| 2.4 | 11.5 | 8 | 4.6 | |
| 20.1 | 28.3 | 37.2 | 37.9 | |
| 0 | −1 | −0.8 | −19.8 | |
| 111 | 118 | 199 | 240 | |
| 23.4% | 23.6% | 24.7% | 23.0% | |
| 84.9 | 90.5 | 149 | 185 | |
| – | +6.6% | +65.1% | +23.9% | |
| 13.89 | 14.80 | 24.43 | 30.27 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 61.2 | 61.2 | 61.2 | 61.2 | |
| 347 | 419 | 545 | 686 | |
| 28 | 159 | 86.2 | 165 | |
| 159 | 191 | 237 | 293 | |
| 595 | 831 | 930 | 1,205 | |
| 257 | 319 | 393 | 438 | |
| 73.4 | 128 | 194 | 147 | |
| 14.5 | 2 | 0.1 | 127 | |
| 20.5 | 3.2 | 3.2 | 1.8 | |
| 229 | 378 | 340 | 492 | |
| 595 | 831 | 930 | 1,205 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 103 | 157 | 190 | 229 | |
| −50.2 | −267 | −83.9 | −256 | |
| −44.7 | 98.5 | −107 | 25.3 | |
| 7.7 | −11.3 | 0.1 | −1.4 | |
| −94.8 | −286 | −91.7 | −174 | |
| 7.9 | −130 | 98.8 | 55.3 | |
| −7 | −16.9 | −22.6 | −44.7 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 19.8% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.